Background: To investigate the difference in frequency of RAS mutations between nodular hyperplasia (NH), follicular thyroid adenomas (FTAs) and follicular thyroid carcinomas (FTCs) in a Korean population. 
| INTRODUC TI ON
Similar to other forms of differentiated thyroid cancer, follicular thyroid cancer most commonly presents as an asymptomatic mass that cannot be distinguished from a benign follicular neoplasm based on cytological, ultrasonography or clinical features alone. The diagnosis of follicular thyroid carcinoma (FTC) is made based on morphology, depending on the presence of capsular and/or vascular invasion in thyroidectomy specimens. [1] [2] [3] Therefore, molecular markers that can help distinguish between FTCs and benign follicular neoplasms, and can also identify life-threatening FTCs, have been investigated.
The BRAF V600E mutation is the most common genetic alteration in thyroid tumorigenesis and has been observed in 29%-83% of papillary thyroid carcinomas (PTCs). [4] [5] [6] RAS mutations are the second most common genetic alteration in thyroid tumours. Recent studies have reported that 10%-20% of PTCs and 40%-50% of FTCs harbour RAS mutations. 3, 7 These mutations have been associated with poor prognoses and tumour dedifferentiation. 8, 9 The RAS genes consist of three families: N-RAS, H-RAS and K-RAS.
RAS point mutations mostly occur in codons 12, 13 and 61. 10, 11 However, the implications for diagnostic detection of RAS mutations by fineneedle aspiration (FNA) or surgical specimens are not clear because RAS mutations occur not only in thyroid cancers, but also in histologically benign nodules including follicular thyroid adenomas (FTAs) and nodular hyperplasia (NH). 12 The frequency of RAS mutations in FTCs and FTAs is controversial, probably because a small number of cases were evaluated in previous studies, which also used different methodologies.
Some reports have suggested that RAS mutations are more prevalent in FTCs than FTAs. [13] [14] [15] However, our preliminary study found no significant difference in the prevalence of any RAS mutation subtype between FTCs and FTAs. 16 After finishing that study, we wondered whether a RAS mutation would be helpful to distinguish NHs from
FTCs and FTAs and eventually reduce unnecessary thyroid surgery.
There is no reliable report describing a RAS analysis of NH to date.
Therefore, the aims of this study were (a) to compare the frequency of RAS mutations among follicular thyroid nodules, (b) to determine differences in RAS mutations between benign NH and follicular neoplasm and (c) to determine if RAS analysis can help reduce unnecessary surgery, if benign NH can be differentiated from follicular neoplasm by RAS analysis.
In the present study, we analysed the clinical significance and diagnostic utility of RAS mutations for differentiating NHs from follicular neoplasms.
| MATERIAL S AND ME THODS

| Materials
Our institutional review board approved the present retrospective study, and the requirement for informed consent was waived. We 
| DNA isolation
Follicular thyroid carcinoma or FTA areas were marked using the H&E-stained sections as a guide. Each marked area was prepared from four to five sections (10 μm thick) using a microtome and transferred to an Eppendorf tube. Microdissected specimens from the paraffin-embedded blocks were subjected to treatment with a deparaffinization solution (Qiagen, Hilden, Germany) to remove the paraffin. DNA was isolated using a QIAamp DNA FFPE Tissue Kit (Qiagen) according to the manufacturer's protocol.
| Detection of K-, N-and H-RAS mutations by pyrosequencing
Primers were designed using PyroMark Assay Design software (ver. 2.0; Qiagen). Polymerase chain reaction (PCR) was performed using a PyroMark PCR Kit (Qiagen) after initial denaturation at 95°C for 15 minutes, followed by 45 cycles of a three-step PCR protocol that included 30 seconds of denaturation at 95°C, 30 seconds of annealing at 60°C and 30 seconds of elongation at 72°C.
This was followed by a final 10-minute extension phase at 72°C.
Briefly, 5 μL genomic DNA was amplified using template-specific PCR primers (including one biotin-labelled primer) and templatespecific PCR conditions. Next, the PCR products were immobilized on streptavidin Sepharose beads, and single-stranded DNA was prepared to allow subsequent annealing of the sequencing primer to the template DNA. Then, the primed single-stranded DNA was released from the streptavidin surface and transferred to a PyroMark Q24 system (Qiagen) for pyrosequencing.
| Statistical analysis
The sex and age of the patients who were analysed for RAS mutations were tabulated ( Table 1 ). The three groups were compared using Student's t test (for patient age) or the chi-square test (for sex).
To 
| RE SULTS
| Patients
The age of the patients ranged from 12 to 82 years (mean, 43.5 years). The mean age of the patients with NH, FTC and FTA was 41.9, 49.3 and 40.9 years, respectively. The patients with FTA were significantly younger than the patients with FTC (P = 0.046). There were 134 female and 12 male patients in this study.
| RAS point mutations
We checked for the presence of N-RAS, H-RAS and K-RAS gene mutations in 50 NHs, 57 FTAs and 39 FTCs ( N-RAS codon 61 (n = 6 of 9, 66.7%; Figure 1 ) and H-RAS codon 61
(n = 3 of 9, 33.3%) were found in NHs. K-RAS codons 12-13, K-RAS (n = 
| D ISCUSS I ON
The presence of RAS mutations suggests the possibility of a broad spectrum of tumours, from benign follicular adenoma to FTC, follicular variants (FVs) of PTC, anaplastic carcinoma and poorly differentiated thyroid carcinoma.
8,17-20
H-RAS, N-RAS or K-RAS participation in the RAS-RAF-MAPK
pathway is essential for controlling the proliferation, differentiation and survival of eukaryotic cells. 21 The H-RAS, N-RAS and K-RAS oncogenic mutations found frequently in human tumours disrupt the normal outcome of those signalling pathways, thus leading to tumour development. FTCs (45.7%) and FTAs (33.9%). 16 According to our previous study, the incidence rate of RAS mutations was not so helpful to differentiate FTCs from FTAs.
16
Several reports have suggested that RAS mutations are most frequently detected on codon 61 of N-RAS in FTCs. 3, 8, 12, 13, [26] [27] [28] On the other hand, other studies have shown that mutations in N-RAS codon 61 predominate in various kinds of follicular thyroid lesion relative to other RAS mutations. 26, 29, 30 We found no significant differences in RAS mutation frequency between The present study may be the first to include a relatively large number of cases (n = 50) and analyse subtypes of RAS mutation in
NHs. In the present study, N-RAS codon 61 was the most frequent not only in FTCs and FTAs but also in NHs. The frequency was not different among the three groups. K-RAS codons 12-13 were the second most commonly involved site in FTCs and FTAs, whereas no mutation was detected in NH. A significant difference was observed in the frequency of the K-RAS codon 12-13 mutation between NHs
The result of pyrosequencing of N-RAS codon 61 mutation found in nodular hyperplasia
The result of pyrosequencing of K-RAS codon 12-13 mutation found in follicular thyroid carcinoma
The result of pyrosequencing of K-RAS codon 12-13 mutation found in follicular thyroid adenoma and FTCs (P = 0.02), although the frequency of the K-RAS codon 12-
mutation was not different between NHs and FTAs or FTCs and
FTAs.
Because we included only surgically proven NHs or follicular neoplasms, we could not evaluate the long-term prognosis or RAS (+) benign nodules. We do not know whether NHs presenting with a RAS mutation have a different prognosis compared to NHs without a RAS mutation. However, one study 31 showed that benign thyroid nodules harbouring RAS mutations had a larger mean volume (P = 0.017) and RAS mutation-positive nodules displayed a mean 27.6% yearly volume increase, during RAS mutation-negative nodules remained unchanged after a 25-month follow-up.
Although no nodules displayed clinical features suspicious
of malignant conversion during follow-up in that study, the authors suggested that more careful follow-up and timely surgical management are needed for thyroid nodules presenting with RAS mutations and benign cytology. A prospective study with a large number of cases and a much longer follow-up would be necessary to assess the prognosis of benign nodules harbouring a RAS mutation.
Several limitations of this study should be mentioned. 
| CON CLUS IONS
The frequencies of RAS mutations among our Korean population were 18% in NHs, 46.2% in FTC and 33.3% in FTAs. N-RAS codon 61 was the most frequent mutation in NHs, FTCs and FTAs, and the frequency was not significantly different among the three groups. K-RAS codons 12-13 were the second most commonly involved site in FTCs and FTAs, whereas no mutation was detected at this site in NHs. A significant difference was observed in the frequency of K-RAS codon 12-13 mutation between NHs and FTCs (P = 0.017).
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